StocksMediumUpdated×2•Originally published 10 November 2026•Updated 10 November 2026•
1 min read
Protalix BioTherapeutics Beats Estimates as Q3 Net Income Rises to $4 Million
Key Facts
1Protalix net income rose to $4.0 million in Q3 2026, up from $2.4 million in the same quarter of 2025.
2Year-to-date total revenues increased to $75.6 million, and management expects to meet or exceed 2026 revenue guidance of $78.0 million to $83.0 million.
Protalix BioTherapeutics reported third-quarter 2026 revenue of $21.9 million, exceeding analyst estimates as net income rose to $4.0 million. PR Newswire reported that the revenue figure included $21.8 million from goods sales and $0.1 million from license and R&D services.
The performance marks an increase in net income from $2.4 million in the prior-year period, bringing year-to-date total revenues to $75.6 million. PLX was trading at $2.57 on November 9, 2026, as management confirmed its full-year 2026 revenue guidance of between $78.0 million and $83.0 million.